ImmusanT Receives $12,000,000 Series B Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Kendall Square Cambridge, MA 02139 USA
  • Company Description
    ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will fund the Phase 2 clinical development of Nexvax2 to demonstrate proof-of-concept as well as continued development of ImmusanT’s diagnostics.
  • M&A Terms
  • Venture Investor

Trending on Xconomy